Page 5 - Simba Gill News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evelo Biosciences, Inc. (EVLO) Q4 2020 Earnings Call Transcript Motley Fool Transcribing © The Motley Fool Logo of jester cap with thought bubble. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q4 2020 Earnings Call Welcome to Evelo Biosciences conference call to discuss the fourth quarter and full-year 2020 financial results and business highlights. [Operator instructions] Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Jessica Cotrone of Evelo. Please proceed. Jessica Cotrone -- Vice President, Head o...

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced

Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones -- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial to 2Q 2021; full dataset expected 2H 2021 -- -- Advance novel anti-inflammatory product candidate EDP1867 in atopic dermatitis into clinic in 1Q 2021; data expected 4Q 2021 -- -- Prepare to advance first extracellular vesicle (EV) product candidates into the clinic in 2022: EDP2939 for inflammation and EDP1908 f...

Evelo Biosciences, Inc.: Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones -- Expand EDP1815 Phase 2 program to include atopic dermatitis; interim clinical results expected in 1Q 2022 -- -- Accelerate delivery of interim clinical data from EDP1815 Phase 2 psoriasis trial to 2Q 2021; full dataset expected 2H 2021 -- -- Advance novel anti-inflammatory product candidate EDP1867 in atopic dermatitis into clinic in 1Q 2021; data expected 4Q 2021 -- -- Prepare to advance first extracellular vesicle (EV) product candidates into the clinic in 2022: EDP2939 for i...

Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer Evelo Biosciences Appoints Industry Veteran Jonathan Zung, Ph.D. as Chief Development Officer CAMBRIDGE, Mass., Dec. 21, 2020 — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced the appointment of Jonathan Zung, Ph.D., as Chief Development Officer and a member of the Evelo Executive Team. Dr. Zung is an established industry veteran,...